Julio Rosenstock
Endocrinology, Diabetes & Metabolism · Dallas, TXNPI 1831133529
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (41.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 36.0% of the total. Among endocrinology, diabetes & metabolism clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 497 payments — averaging $2324.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$416K
- Novo Nordisk AS$280K
- Boehringer Ingelheim International GmbH$97K
- Eli Lilly$69K
- Lilly USA, LLC$48K
- Boehringer Ingelheim B.v.$43K
- plus $202K from 27 others
Across 8,827 payments — averaging $2722.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$13.5M
- Novo Nordisk AS$4.6M
- Sanofi US Services Inc.$1.3M
- Boehringer Ingelheim$1.1M
- Pfizer$932K
- Novartis$806K
- plus $1.8M from 16 others
What the payments were for
- Consulting fees$483,25942%
- Speaking & faculty fees$373,38332%
- Travel & lodging$288,66125%
- Food & beverage$9,0961%
- Education$6860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 87 | $415,510 |
| Novo Nordisk AS | 94 | $280,421 |
| Boehringer Ingelheim International GmbH | 54 | $97,280 |
| Eli Lilly | 90 | $69,397 |
| Lilly USA, LLC | 10 | $47,674 |
| Boehringer Ingelheim B.v. | 7 | $42,995 |
| Sanofi US Services Inc. | 16 | $40,874 |
| Novo Nordisk | 17 | $25,643 |
| Boehringer Ingelheim | 28 | $24,160 |
| Regeneron | 26 | $20,744 |
| Boehringer Ingelheim Do Brasil Quimica E Farmaceutical Ltda. | 4 | $20,094 |
| Zealand Pharma US, Inc. | 11 | $11,940 |
| F. Hoffmann-la Roche AG | 10 | $10,890 |
| Applied Therapeutics, Inc. | 5 | $8,414 |
| Boehringer Ingelheim Mexico SA De CV | 2 | $8,000 |
| Amgen | 9 | $7,700 |
| Boehringer Ingelheim India Pvt. Ltd. | 2 | $7,000 |
| Zealand Pharma A/s | 1 | $4,688 |
| Boehringer Ingelheim Hong Kong Ltd. | 1 | $4,000 |
| Ferring Pharmaceuticals AS | 1 | $2,965 |
| Mannkind Corporation | 6 | $1,671 |
| Lexicon Pharmaceuticals, Inc. | 1 | $1,661 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $1,000 |
| Janssen Scientific Affairs, LLC | 1 | $123 |
| Corcept Therapeutics | 1 | $50 |
| Abbott | 2 | $43 |
| Dexcom, Inc. | 3 | $39 |
| AstraZeneca | 1 | $27 |
| Johnson & Johnson | 2 | $25 |
| Gilead | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $15 |
| Optos, Inc. | 1 | $14 |
| Nevro Corp. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$334,660
- TRADJENTA$89,561
- JARDIANCE$68,008
- NO PRODUCT DISCUSSED$58,944
- TOUJEO$40,547
- MOUNJARO$36,954
- GLYXAMBI$24,094
- RYBELSUS$22,233
- Victoza$13,715
- ZEGALOGUE$11,853
- Dasiglucagon$4,688
- SOTAGLIFLOZIN$3,906
- AFREZZA$1,569
- INVOKANA$123
How this compares
$1,155,085 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metformin Hcl | 16 | $198 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Dallas
- Pablo MoraDallas$1.3M
- Steve FordanDallas$1.2M
- Saleemah FahmiDallas$1.2M
- Ildiko LingvayDallas$711K
- Rajiv DattatreyaDallas$437K
- Jaime AlmandozDallas$334K
- Luigi MeneghiniDallas$136K
- Oksana HamidiDallas$106K
- Lance SloanLufkin$1.7M
- Robert HoodBeaumont$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.